Assessing Krüppel-Like Factors in Bone Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the prognostic significance of Krüppel-like factors 4 and 7 in children and young adults diagnosed with osteosarcoma and Ewing sarcoma. By analyzing tissue expression of these proteins, the study seeks to understand their role in disease progression and potential outcomes. Participants will undergo a thorough medical history review and physical examination to gather relevant data on symptoms and treatment protocols. The study will be conducted over a 12-month period at Ain Shams University Children's Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Age: children, young adolescents younger than 15 years, and young adults (15 to 39 years) Gender: Males and female. Histologically confirmed patients with skeletal or extra-skeletal OS or ES. Both localized and metastatic disease stages.

Exclusion Criteria:

Patients with second malignant bone sarcoma. Patients with benign bone tumors.

Where it's running

• Ain Shams University
  Cairo, Egypt Recruiting
• Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC)
  Cairo, Egypt Recruiting

Study contacts

• Principal investigator: Fatma S E Ebeid — Faculty of Medicine Ain Shams University
• Study coordinator: Fatma S E Ebeid, MD
• Email: fatmaebeid@med.asu.edu.eg
• Phone: 01095569596

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Higher methotrexate discharge after standard osteosarcoma chemo

  In newly diagnosed osteosarcoma patients 22 or younger, this study tests whether they can go home earlier with higher methotrexate levels after standard HD-MTX-based chemotherapy.

  Recruiting at 2 sites Phase 2 Wake Forest University Health Sciences · Chapel Hill, North Carolina and 8 other locations · NCT07560826

• Tegavivint plus gemcitabine for relapsed or refractory osteosarcoma

  This trial tests whether adding tegavivint to gemcitabine is safe and can help people whose osteosarcoma has come back or not responded to prior treatment.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT07144254

• Evaluating the safety and effectiveness of OMO-103 for advanced high-grade osteosarcoma

  This study is testing a new treatment called OMO-103 to see if it can safely help people with advanced high-grade osteosarcoma.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06650514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.